Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Abstract

Background RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points. Patients and… (More)
DOI: 10.1093/annonc/mdx075

Topics

4 Figures and Tables

Cite this paper

@inproceedings{Knox2017FinalOS, title={Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC}, author={J. J. Knox and Clara Barrios and Tae-Eun Kim and Thomas Michael Cosgriff and Vichien Srimuninnimit and K. J. Pittman and Roberto Sabbatini and So Young Rha and Thomas W. Flaig and Rebecca Page and Johannes Beck and F. Cheung and S. Yadav and P. Patel and Lionnel Geoffrois and Julie Niolat and Noah C Berkowitz and Mahtab Marker and D. Chen and Robert J Motzer}, booktitle={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2017} }